Case Reports in Hematology / 2019 / Article / Tab 1

Case Report

An Unusually Short Latent Period of Therapy-Related Myeloid Neoplasm Harboring a Rare MLL-EP300 Rearrangement: Case Report and Literature Review

Table 1

A summary of cases of therapy-related MLL-EP300-positive leukemia (cases 1–4).

CaseAge/sexPhenotypeKaryotypeMLL-EP300 breakpointLatent period (months)Primary malignancyCytotoxic exposureReference

14/MAML48,XY, +8, +8, t(11;22)(q23;q13)MLLexon9/EP300exon1567NHLChemo including ETP[16]

25/FAML46,XX, t(1;22;11)(q44;q13;q23), t(10;17)(q22;q21)MLLexon7/EP300exon1536NeuroblastomaChemo including THP,[17]

366/MAML46,XY, t(11;22)(q23;q13). idem, +8MLLexon10, 11/EP300exon1316PTCL NOS, AML with MDSCBDCA, CPA CHOP-14, ESHAP[18]

462/FCMML46,XX, t(11;22)(q23;q13)MLLexon10/EP300exon1510ATLmLSG+ mogamulizumabPresent case

CHOP-14 contains cyclophosphamide, doxorubicin, vincristine, and prednisolone. ESHAP consists of etoposide, methylprednisolone, cytarabine, and cisplatin. ETP, etoposide; THP, pirarubicin; CBDCA, carboplatin; CPA, cyclophosphamide. mLSG contains VCAP (vincristine, cyclophosphamide, doxorubicin, and prednisone), AMP (doxorubicin, ranimustine, and prednisone), and VECP (vindesine, etoposide, carboplatin, and prednisone). NHL, non-Hodgkin lymphoma; PTCL NOS, peripheral T-cell lymphoma not otherwise specified; ATL, adult T-cell leukemia/lymphoma.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.